Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) is -72.15% lower on its value in year-to-date trading and has touched a low of $2.83 and a high of $23.12 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ZNTL stock was last observed hovering at around $4.36 in the last trading session, with the day’s loss setting it -0.14%.
Currently trading at $4.22, the stock is 25.60% and 18.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.84 million and changing -3.21% at the moment leaves the stock -58.02% off its SMA200. ZNTL registered -81.26% loss for a year compared to 6-month loss of -69.22%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 27.88% gain in the last 1 month and extending the period to 3 months gives it a -11.16%, and is 30.25% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 17.77% over the week and 10.19% over the month.
Zentalis Pharmaceuticals Inc (ZNTL) has around 168 employees, a market worth around $300.08M and $40.56M in sales. Profit margin for the company is -479.92%. Distance from 52-week low is 49.12% and -81.75% from its 52-week high. The company has generated returns on investments over the last 12 months (-45.92%).
The EPS is expected to grow by 35.18% this year.
Zentalis Pharmaceuticals Inc (ZNTL) Top Institutional Holders
208.0 institutions hold shares in Zentalis Pharmaceuticals Inc (ZNTL), with institutional investors hold 112.72% of the company’s shares. The shares outstanding are 70.77M, and float is at 61.33M with Short Float at 20.02%. Institutions hold 108.23% of the Float.
The top institutional shareholder in the company is MATRIX CAPITAL MANAGEMENT COMPANY, LP with over 13.96 million shares valued at $57.1 million. The investor’s holdings represent 19.6902% of the ZNTL Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 8.68 million shares valued at $35.49 million to account for 12.2383 of the shares outstanding. The other top investors are EVENTIDE ASSET MANAGEMENT, LLC which holds 8.55 million shares representing 12.0566% and valued at over $34.96 million, while VANGUARD GROUP INC holds 7.9759 of the shares totaling 5.65 million with a market value of $23.13 million.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity
The most recent transaction is an insider sale by Gallagher Cam, the company’s President, Interim CFO. SEC filings show that Gallagher Cam sold 9,597 shares of the company’s common stock on May 31 ’24 at a price of $11.98 per share for a total of $0.11 million. Following the sale, the insider now owns 0.63 million shares.
Zentalis Pharmaceuticals Inc disclosed in a document filed with the SEC on May 09 ’24 that HAUSMAN DIANA (Chief Medical Officer) sold a total of 3,356 shares of the company’s common stock. The trade occurred on May 09 ’24 and was made at $12.62 per share for $42353.0. Following the transaction, the insider now directly holds 0.37 million shares of the ZNTL stock.
Still, SEC filings show that on Feb 12 ’24, Epperly Melissa B, (Chief Financial Officer) disposed off 2,573 shares at an average price of $11.44 for $29435.0. The insider now directly holds 451,449 shares of Zentalis Pharmaceuticals Inc (ZNTL).
